Merck’s (NYSE: MRK) Q1 2025 results reflect strong progress, including increasing contributions from newer medicines and vaccines. Our company announced Q1 worldwide sales of $15.5 billion.
“Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline,” said Rob Davis, chairman and chief executive officer. “We are working with focus and urgency to both realize the full potential of our near-term opportunities and to rapidly progress the next wave of innovation that will positively impact the lives of patients and drive future value creation for all of our stakeholders.”
Merck anticipates full-year 2025 worldwide sales to be between $64.1 billion and $65.6 billion.
Take a look at the infographic below for more details on Q1 2025 results.
There are so many unknowns after a cancer diagnosis — whether or not you receive support at work shouldn’t be one of them
April 17, 2025
Share this article
youtube
https://www.youtube.com/watch?v=sMAFyJuH51g
:
Chet Kitchen had no idea how his battle with cancer would affect his work. Our colleague of 25 years and director of global regulatory policy wasn’t used to missing big meetings and presentations for hospital visits and oncology appointments.
“It’s a constant balance between trying to focus on work and trying to focus on your health,” said Kitchen. “That’s where having a good company to support you and colleagues who appreciate you and look out for you can make the difference.”
Kitchen is a head and neck cancer survivor. After following his doctor’s treatment plan for stage 4 squamous cell carcinoma of the tonsil, he was told there was no evidence of disease. But a year later, the cancer returned, and he was put on a new treatment plan.
Head and neck cancer can begin in or around the throat, voice box, sinuses, mouth and salivary glands. More than 90% of head and neck cases are squamous cell carcinoma, which is cancer that starts in the cells that line the mucosal surfaces of the head and neck. Symptoms may include a lump in the neck or sore in the mouth or throat that does not heal or may be painful, a sore throat that does not go away, difficulty swallowing, and a change or hoarseness in the voice.
Impact of cancer on careers
“One of the most important things a company can do to support a colleague living with cancer is to listen and understand their needs,” Kitchen said.
“To have the opportunity to take time off was so important,” he said. “My company gave me the flexibility to take care of my emotional needs by allowing me to focus on my health when I needed to, but also to focus on work when I didn’t want to think about cancer.”
Ongoing employment and return to work may help promote a sense of normalcy and control for cancer patients.
“Being diagnosed with cancer may hurt your career or make it more challenging,” Kitchen said.
“But working for our company really invigorated me. I can really appreciate the work that we do and how it impacts patients.”
— Chet Kitchen
Why we support the Working with Cancer pledge
At Merck, we’re dedicated to supporting people living and working with cancer around the world. We’re proud to be an accredited CEO Cancer Gold Standard employer and a founding member of the Working with Cancer pledge to help provide a more open, supportive and recovery-forward culture at work for cancer patients like Kitchen.
Today, Kitchen’s cancer is in remission, but that doesn’t mean his patient journey is over.
“Even though you’re not physically battling cancer, it never really leaves you because it’s always somewhere in your mind,” he said. “But one of the things that’s really helped me emotionally through my survivorship is sharing my story.”
Understanding melanoma: The signs and risk factors
Learn more about how to monitor your skin for melanoma and ways to help prevent it
March 26, 2025
Share this article
What is melanoma?
Melanoma is a form of skin cancer. Characterized by the uncontrolled growth of pigment-producing cells, melanoma accounted for approximately 1.7% of new cancer cases worldwide in 2022.
Exposure to ultraviolent (UV) radiation, either from the sun or other sources such as tanning beds and sunlamps, is a major risk factor for skin cancers, including melanoma. While melanoma can occur anywhere on the skin, including areas without sun exposure, it’s more likely to start in certain locations, like the face and neck, legs (most common in women), and chest and back (most common in men).
The risk of melanoma generally increases with age and incidence is greater among older populations. However, even among patients younger than 30 years, melanoma is one of the most common cancers, especially in young women.
Worldwide, the melanoma diagnosis rate has risen over the past two decades
331,000+
Estimated number of new melanoma cases worldwide in 2022
Signs of cancerous moles
A new spot on the skin or a spot that is changing in size, shape or color, or one that looks different, is an important warning sign of melanoma and should be checked by a doctor. The ABCDE rule can be used as a guide to help identify the warning signs of melanoma:
A is for Asymmetry
One half of a mole or spot does not match the other.
B is for Border
The edges of the spot are irregular, scalloped or poorly defined.
C is for Color
The color of the spot is not the same all over and may include different shades of brown or black, sometimes with patches of pink, red, white or blue.
D is for Diameter
The spot is larger than 6 millimeters across. Melanoma is usually larger than 6 millimeters in size (about 1/4-inch or the size of a pencil eraser) when diagnosed. However, it can sometimes be smaller.
E is for Evolving
The mole is changing in size, shape, or color.
Any of these warning signs should be discussed with a doctor, especially if you feel you are at risk for melanoma.
Causes of melanoma
There are many risk factors and causes of melanoma, including:
UV light on your skin, such as from the sun or a tanning bed (the most common risk factor for most cases of melanoma)
Age — melanoma is more common in older people, but younger people are also at risk. Melanoma is one of the most common cancers in people younger than 30 years (especially among women)
Moles — having many moles, irregular or large moles, or atypical moles
Personal or family history – Melanoma can be genetic and having a relative with melanoma can increase your risk
Fair skin or a fair complexion, a lot of freckles and/or light-colored hair and eyes
Ways to lower your risk of melanoma
Melanoma can’t be entirely prevented, but there are ways to lower your risk. The number one way to lower risk is to protect against UV rays, which damage the DNA of skin cells and impact the genes that control skin cell growth. That’s why it’s important to avoid tanning beds, booths, sunlamps and other artificial sources of UV radiation. However, the top source of UV rays is the sun. That’s why it’s important to practice sun safety every time you go outside, even on cloudy days when UV rays can still shine through. Here are a few ways to protect yourself:
Seek shade
UV exposure is greatest between the hours of 10 a.m. and 4 p.m. If you need to be outside during these hours, seek shade – under a tree, an umbrella or an awning.
Wear a hat
Try to find a hat with a wide brim – at least 2 or 3 inches wide – to protect your face, top of the head, ears and neck.
Cover up
Choose clothing with a tight knit or weave, and avoid shirts that you can see through. Remember, if light is getting through, then UV rays are too.
Use sunscreen
For extended outdoor activity, use a water-resistant, broad spectrum sunscreen with an SPF of 30 or higher.
Wear sunglasses
Protect your eyes and the sensitive skin around them. Pick a pair of sunglasses that will block as close to 100 percent of both UVA and UVB rays as possible.
Stories of research and clinical care from two leading experts in pneumococcal and pediatric infectious disease
March 19, 2025
Share this article
Nearly all of us have caught a seasonal cold, but some infectious diseases can pose significant health risks. Research plays a critical role in advancing prevention and treatment strategies for infectious diseases.
Our researchers are at the forefront of scientific innovation, working to address the diseases that threaten our most vulnerable populations around the world. Heather Platt, M.D., and Marissa Wilck, M.D., two Merck scientists specializing in pneumococcal and pediatric infectious diseases, shared their journeys into medicine and their reflections on the critical role research plays in improving public health.
What drew you to a career in infectious disease research?
Dr. Wilck: “I grew up in rural South Africa and had to choose a career at 18. Knowing amazingly little about what it would encompass, I chose med school because of my love of science and wanted to do something meaningful with my life. In my clinical years, I saw infectious diseases all around me, which drove me to specialize in infectious diseases.”
Dr. Marissa Wilck
Dr. Platt: “I chose internal medicine for my residency because I loved learning the broad scope and it allowed me to explore a variety of interests, particularly in infectious diseases.
One of my first patients during my internship year was a 75-year-old lady who had pneumonia and was brought into the ICU because her blood pressure was starting to drop. Within an hour, she needed full support for breathing and blood pressure with central lines and intubation. That was a pivotal moment for me to understand the complexity and impact of infectious diseases like pneumococcal disease. I later completed a fellowship in infectious diseases and witnessed advancements that made me want to pursue research.”
Are there any common misconceptions about infectious diseases like pneumococcal disease that you aim to overcome?
Platt: “Anyone can get pneumococcal disease. You’re at increased risk depending on your age or certain medical conditions. Some people can become very ill, very quickly. I think Marissa and I have both seen serious cases of complications from pneumococcal disease, like pneumonia and meningitis.”
Wilck: “In my clinical years, I remember seeing previously healthy people becoming very sick with pneumococcal disease. I have a particular patient in mind that I think about; I remember looking at him and thinking, ‘How can this strong man who was healthy just two or three weeks ago get so sick from this bacteria?’”
Approximately 13.7 million people worldwide died from infectious diseases in 2019.
Infections such as pneumococcal disease can lead to potentially severe health issues, like pneumonia, sepsis and meningitis.
Pneumonia impacts millions of people worldwide each year.
What makes infectious disease research unique compared to other areas of medical research?
Wilck: “I find infectious disease research fascinating because it encompasses many aspects of human health and society. Infectious diseases affect everyone, and the social and economic impacts touch all communities. To me, this has reinforced the critical importance of researching prevention measures. We have the opportunity to make such a difference.”
How do we balance research in prevention versus treatment?
Dr. Heather Platt
Platt: “There’s a lot of satisfaction that comes from knowing that you can be a part of preventing disease. But as infectious disease physicians, we see how prevention and treatment both have a role. Choosing to spend time on prevention strategies is as worthy as the time that our colleagues are spending on researching treatments for these diseases. We can put our collective heads together because we’re all fighting for the same thing.”
What inspires you about our team?
Wilck: “Merck has such a deep history and legacy in infectious disease research and innovation. As a team, we can make things happen in a way that we could never do as individuals. I’m proud to be part of that effort.”
Platt: “At Merck we have the opportunity to work in different therapeutic areas, and that allows me to appreciate the different elements of research that are needed in order to improve the burden of these infectious diseases. It isn’t just one product or one patient. Marissa and I have crisscrossed paths in our research in pneumococcal and pediatric infectious diseases at Merck, but we’ve both had the opportunity to positively contribute to public health. It’s an honor and a privilege to be a part of offering prevention options.”
We’ve been working to combat global health threats caused by infectious diseases for more than a century. Learn more about our work in infectious disease research.
Health awareness
VIDEO: Living with pulmonary arterial hypertension
One woman’s story shows the power of knowledge and support for patients with pulmonary arterial hypertension (PAH)
March 18, 2025
Share this article
youtube
https://www.youtube.com/watch?v=-WjsxxOeOVU
:
Pulmonary arterial hypertension (PAH) entered Colleen’s life unexpectedly. She was 35 when she noticed she became short of breath easily. She thought it was due to the weight she gained during her recent pregnancy. A year later, Colleen lost the weight but was still gasping for breath after climbing a few flights of stairs. Colleen wasn’t only feeling fatigued; she was worried. She’d later learn these were symptoms of PAH.
Colleen was first diagnosed with asthma, but her condition continued to worsen. She searched for an answer while daily tasks became more difficult. It took two and a half years for Colleen to be referred to a cardiologist who properly diagnosed her with PAH, one of the five different types of a broader condition called pulmonary hypertension (PH).
What is pulmonary arterial hypertension (PAH)?
PAH is a rare and life-threatening condition that progressively worsens. It is a type of high blood pressure in the small arteries of the lungs. This condition occurs when these vessels thicken, narrowing the space for blood to flow and leading to increased pressure in the pulmonary circulation. As a result, the right side of the heart must work harder to pump blood through these arteries. Over time, the right side of the heart can become weakened and lose function.
PAH has similar symptoms to other common lung diseases, such as asthma, which can make it difficult to diagnose. Currently, there are approximately 1,000 people in the U.S. diagnosed with PAH each year.
Recognizing the signs and symptoms of PAH
The exact cause of PAH is unknown, and most people with PAH have no known family history of the disease. People may not notice any early-stage symptoms of PAH, but as the disease progresses, they may experience common symptoms, such as increased shortness of breath, peripheral edema (swelling of the feet and/or legs), fatigue, dizziness, fainting spells, and heart palpitations (racing heart).
PAH can hinder a person’s physical abilities and impact everyday tasks.
“Living with pulmonary arterial hypertension isn’t easy.”
Colleen, patient with PAH
“I had to purchase a scooter to do outside activities with my children. I couldn’t perform basic functions for myself and my family or make it to the sidelines of a baseball field to watch my son play. I was truly relegated to living on the sidelines myself. But through it all, I’ve never given up,” said Colleen.
Raising awareness for PAH
In addition to working with her doctor, Colleen found comfort through her support system. Since her diagnosis, Colleen has dedicated her life to raising awareness of PAH and helping others living with the disease. “It’s important for patients and the community to have knowledge and encourage each other. Whatever we can do to lift the community and spread awareness of this devastating disease is appreciated,” she added.
Learn more about what the measles virus is and how measles spreads
March 13, 2025
Share this article
What is measles?
Measles is a highly contagious viral disease that can affect people of all ages but is most common in children. The virus lives in the mucus of the nose and throat of an infected person.
Measles spreads through the air when an infected person coughs or sneezes. Symptoms appear 7 to 14 days after contact with the virus.
Common measles symptoms include:
High fever
(may spike to more than 104°F)
Cough
Runny nose
Red, watery eyes
(7-14 days after contact with the virus)
Spots in mouth
(2-3 days after symptoms begin)
Rash
(3-5 days after symptoms begin)
How measles spreads
Is measles airborne?
The measles virus can live for up to two hours in an airspace after an infected person leaves an area.
How contagious is measles?
If one person has measles, up to 90% of
unvaccinated people close to that person will also become infected.
How long is measles contagious for?
Infected people can spread measles to others four days before through four days after the rash appears.
How long is the measles incubation period?
After being exposed to the measles virus, it can incubate for up to 21 days. An incubation period is how long it takes for you to develop symptoms after exposure to an infectious disease.
Does measles cause complications?
Measles can cause health complications. Common complications include ear infections and diarrhea. Serious complications include pneumonia and encephalitis (an inflammation of the brain). Measles may impact the daily lives of patients and their caretakers (e.g., can result in lost work time or missed school days).
Measles can be serious and lead to complications
About 1 in 5unvaccinated people in the U.S. who get measles are hospitalized.
As many as 1 out of every 20 children with measles get pneumonia, the most common cause of death from measles in young children.
Approximately1 to 3 of every 1,000 children who become infected with measles will die from respiratory and neurologic complications.
Understanding measles outbreaks
Before the vaccine became available in 1963, an estimated 3 to 4 million Americans contracted measles each year; an estimated 48,000 people in the U.S. were hospitalized and there were approximately 400 to 500 deaths annually.
Endemic (regularly occurring within an area or community) measles was declared eliminated in the U.S. in 2000.
2019 saw the greatest number of measles cases reported in the U.S. since 1992.
2024 has seen continuous measles outbreaks with 13 measles outbreaks as of July reported across the U.S.
When you’re contagious with measles, up to 90% of the people around you who are not vaccinated will also become infected.
In the U.S., measles cases can originate from international travel as the disease remains common in many parts of the world. Typically, 2 out of 3 of travelers with measles are unvaccinated Americans re-entering the country.
As seen by the recent outbreaks across the country, measles can spread rapidly, and infected individuals can spread measles to other people who are not immune.
For more information, including the latest statistics on outbreaks, speak with your doctor or visit the CDC website.
Our scientists harness rapidly evolving tech in small molecule lead optimization, which aims to improve biological activity, target selectivity and potential for toxicity
February 26, 2025
Share this article
youtube
https://www.youtube.com/watch?v=FPMhBekEYtc
:
The aim in lead optimization is to improve biological activity, target selectivity and potential for toxicity. During this phase of drug discovery, we use artificial intelligence and machine learning (AI/ML) to enhance the properties of lead compounds and evaluate their effects on various biological properties.
The landscape for AI/ML is evolving and maturing at an incredible rate. The convergence of increasing access to relevant data, exponentially available computing power, and advancements in deep-learning algorithms has led to unprecedented opportunities to dramatically accelerate and improve the discovery of new drugs.
Explore R&D careers
We’re looking for next-gen scientists and technologists who are passionate about making a difference for patients.
Obtenga más información sobre qué es el virus del sarampión y cómo se propaga
February 19, 2025
Share this article
¿Qué es el sarampión?
El sarampión es una enfermedad viral altamente contagiosa que puede afectar a personas de todas las edades, pero es más común en los niños. El virus vive en la mucosidad de la nariz y en la garganta de una persona infectada.
El sarampión se propaga por el aire cuando una persona infectada tose o estornuda. Los síntomas aparecen entre 7 y 14 días después del contacto con el virus.
Los síntomas comunes del sarampión incluyen los siguientes:
Fiebre alta
(puede subir repentinamente a más de 104 °F)
Tos
Moqueo
Ojos rojos y llorosos
(conjuntivitis)
Manchas en la boca
(2-3 días después de que comiencen los síntomas)
Erupción
(3-5 días después de que comiencen los síntomas)
Cómo se propaga el sarampión
¿El sarampión se transmite por el aire?
El virus del sarampión puede permanecer hasta dos horas en el ambiente después de que una persona infectada abandona un sitio.
¿Qué tan contagioso es el sarampión?
Si una persona tiene sarampión, hasta el 90% de las personas no vacunadas que se encuentren cerca de ella también se infectarán.
¿Por cuánto tiempo es contagioso el sarampión?
Las personas infectadas pueden transmitir el sarampión a otras entre cuatro días antes y cuatro días después de que aparezca la erupción
¿Cuánto dura el período de incubación del sarampión?
Después de estar expuesto al virus del sarampión, este puede incubarse por hasta 21 días.
¿El sarampión causa complicaciones?
El sarampión puede causar complicaciones de salud. Las más comunes son las infecciones de oído y la diarrea. Las complicaciones graves incluyen neumonía y encefalitis (inflamación del cerebro). El sarampión puede afectar la vida diaria de los pacientes y de sus cuidadores (por ejemplo, puede dar lugar a una pérdida de horas de trabajo o días de escuela).
El sarampión puede ser grave y causar complicaciones
Aproximadamente 1 de cada 5 personas no vacunadas en los EE. UU. que contraen sarampión se hospitalizan.
Hasta 1 de cada 20 niños con sarampión contrae neumonía, que es la causa más común de muerte por sarampión en niños pequeños.
Aproximadamente entre 1 y 3 de cada 1,000 niños que se infectan de sarampión morirán por complicaciones respiratorias y neurológicas.
Brotes de sarampión
Antes de la disponibilidad de la vacuna en 1963, se estima que entre 3 y 4 millones de estadounidenses contraían sarampión cada año, y se calcula que 48,000 personas en Estados Unidos se hospitalizaban y se producían aproximadamente entre 400 y 500 muertes al año.
El sarampión endémico (que ocurre regularmente dentro de un área o una comunidad) se declaró erradicado en los EE. UU. en el año 2000.
En 2019, se registró el mayor número de casos
de sarampión notificados en Estados Unidos
desde 1992.
En 2024, se han producido brotes continuos de sarampión. Hasta julio, se han notificado 13 brotes de sarampión en los Estados Unidos.
Los casos de sarampión han aumentado en los Estados Unidos
Hasta julio de 2024, se confirmaron 167 casos de sarampión en los EE. UU.
Cuando usted se contagia de sarampión, hasta el 90% de las personas a su alrededor que no estén vacunadas también se infectarán.
En los Estados Unidos, los casos de sarampión pueden originarse en viajes internacionales, ya que la enfermedad sigue siendo común en muchas partes del mundo. Por lo general, 2 de cada 3 viajeros con sarampión son estadounidenses no vacunados que reingresan al país.
Como lo demuestran los brotes recientes en todo el país, el sarampión se puede propagar rápidamente y las personas infectadas pueden contagiar a personas que no son inmunes.
Para obtener más información, incluidas las últimas estadísticas sobre los brotes, hable con su médico o visite el sitio web de los Centros para el Control y la Prevención de Enfermedades (Centers for Disease Control and Prevention, CDC).
Merck’s (NYSE: MRK) Q4 and full-year 2024 results reflect strong growth. Our company announced Q4 worldwide sales of $15.6 billion, an increase of 7% from Q4 2023. Full-year 2024 worldwide sales were $64.2 billion, an increase of 7% from full-year 2023.
“We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including for KEYTRUDA, the successful launch of WINREVAIR and strong performance of our Animal Health business,” said Rob Davis, chairman and chief executive officer. “We’re continuing to progress our pipeline, advance key clinical programs and augment our pipeline through promising business development. Our business remains well positioned thanks to the dedication of our talented global team, and I am more confident than ever in our long-term growth potential.”
Merck anticipates full-year 2025 worldwide sales to be between $64.1 billion and $65.6 billion.
Find more details on Q4 and full-year 2024 results below.
Our researchers incorporate LLMs to accelerate drug discovery and development
What are artificial intelligence (AI) agents? They're intelligent systems combining large language models (LLM), AI models and tools to iteratively plan, execute and optimize tasks
February 3, 2025
Share this article
Did you know that LLMs can be leveraged as master multitaskers? These LLM-based multitaskers, often called AI agents, can execute different tasks simultaneously. Having a team of high-performing AI assistants that can each play different roles ultimately helps researchers at Merck Research Labs (MRL) focus on critical drug discovery and development.
In today’s data-driven world, AI agents are emerging as a powerful tool for researchers and scientists to aid them in navigating the complexities of large data sets, refining hypotheses and executing both repetitive and differentiated tasks efficiently. Done manually, that kind of data gathering and analysis costs time and money.
Merck researchers use AI to augment human ability
A long-standing ambition for AI is to help find major scientific discoveries, learn on its own and acquire knowledge autonomously. This is what some call an “AI scientist.” While this concept is aspirational, advances in agent-based AI can help pave the way for the development of AI agents as conversable systems capable of reflective learning and reasoning that coordinate LLMs, machine learning (ML) tools, or even combinations of them.
Rather than taking humans out of the discovery process, AI can augment human ability to break down a problem into manageable subtasks, which can then be addressed by AI agents with specialized functions for targeted problem solving and integration of scientific knowledge. One significant advantage of these collaborative systems is their capacity for automation. Repetitive tasks, such as data cleaning or preliminary analysis, can be handled by AI agents, freeing our scientists to focus on higher level work and strategic decision making.
“We’ve already deployed AI agents, including in development workflows like medical writing, where agents query and assemble knowledge, and evaluate both human and AI writing.”
Matt Studney Senior vice president, information technology, MRL
“We see broad applicability of AI agents, for example in orchestrating discovery workflows, where agents can help researchers in generating molecular design ideas and insights, optimize assay workflows and generate biology insights integrated across cells, organisms and human genomics,” he said. “We see agents making the R&D process faster and crucially driving higher quality results. Agents help capitalize on Merck’s long-standing investments in AI/ML by rapidly accelerating the speed of our human researchers at scale.”
Advance your data science career with us
We’re looking for scientists and technologists who are passionate about making a difference for patients.
Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
This website of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.
By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Rahway, NJ USA.
